News Article

Zebra Biologics Inc. to Collaborate with AbbVie to Discover New Antibody Therapeutics
Date: Jan 09, 2017
Source: Business Wire ( click here to go to the source)

Featured firm in this article: Zebra Biologics Inc of Concord, MA

CONCORD, Mass.--(BUSINESS WIRE)--Zebra Biologics Inc., an emerging pre-clinical stage biotechnology company, today announced that the company has entered into a collaboration with AbbVie to discover agonist antibody therapeutics for inflammatory diseases. Zebra will use its novel and patented function-based antibody discovery platform to generate antibodies that activate biological pathways associated with targets designated by AbbVie. Zebra and AbbVie will collaborate closely on the identification and pre-clinical evaluation of emerging candidates. The targets were not disclosed.

Under the terms of the agreement, Zebra will lead the discovery of candidate agonist antibodies for designated targets and will collaborate with AbbVie in pre-clinical validation of select clinical candidates. Upon advancement of clinical candidates, AbbVie would be responsible for clinical development, manufacturing, regulatory approval and world-wide commercialization. Financial terms were not disclosed.

"This collaboration is an important step in the evolution of Zebra from an early stage discovery company toward our vision of developing ground breaking biologic drug therapies for many serious medical conditions," said Ronald M. Lindsay, PhD., Chairman & Chief Executive Officer at Zebra. "Since inception in 2013, we have focused on expanding the application of Zebra's core technology to multiples types of drug targets across a broad spectrum of therapeutic areas. We are now very pleased to enter into a significant collaboration with AbbVie, the world's leader in developing biologic therapies for painful and debilitating inflammatory diseases."

About Agonist Antibodies

To date all clinically approved antibody therapeutics exert their effect by blocking (antagonizing) signaling between ligands and receptors or by neutralizing pathogens. Rare antibody molecules may also activate biochemical pathways, although finding such "agonist" antibodies has proven difficult. As demonstrated in key peer-reviewed publications, the recently developed Zebra screening platform opens up a novel biological function-based approach to screening very large combinatorial antibody or other peptidic libraries for potent and highly selective agonist biologic drugs.

About Zebra Biologics

Zebra is a privately held pre-clinical stage biopharmaceutical company. The Company is pioneering the development of platform technologies that allow cellular function-based screening for the discovery and selection of fully human therapeutic biologics (antibodies, peptides or proteins) from DNA-encoded combinatorial libraries of human antibodies, peptides or "protein-in-proteins". Applicable for lead discovery across all therapeutic areas and all receptor classes, Zebra has optimized the platform for the highly desirable feature of allowing selection of rare agonist antibodies from very large combinatorial libraries.

Zebra holds exclusive licenses from the The Scripps Research Institute to both the core platform technology and to current and future candidate therapeutics derived from the platform. Multiple proof of concept examples of the power of Zebra's platform have been published by the laboratory of Dr. Richard Lerner, a Zebra co-founder and Professor at Scripps. Zebra is advancing an internal portfolio of novel full human agonist antibodies and novel highly selective ion-channel blockers.

Zebra Biologics Inc.
Ronald M. Lindsay, 978-505-8719